JPRN-UMIN000004797已完成3 期
Clinical Study on the Efficacy and Safety of Z101101 in Total Hip Arthroplasty - Clinical Study on the Efficacy and Safety of Z101101 in Total Hip Arthroplasty
Zimmer K.K.0 个研究点目标入组 69 人开始时间: 2011年1月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 21years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The patient is a known alcohol or drug abuser. 2) The patient has a neuromuscular disorder, vascular disorder or other condition that could cause implant instability, implant fixation failure, or postoperative complications. 3) The patient has a vascular insufficiency (large and small vessel disease), renal impairment, or renal failure. 4) The patient has initiated a chronic administration of systemic or inhaled steroid within 3 months. 5) The patient has a neurologic condition that could affect the function of the lower limbs. 6) The patient needs to be corrected a leg length discrepancy >= 3.2 cm. 7) The patient has a systemic disease that could affect his/her safety or the study outcome. 8) The patient has a contagious disease and is difficult to continue observation/investigation. 9) The patient is known to be pregnant. 10) The patient has received an investigational drug or other investigational device within the previous 6 months. 11) The patient has an active or latent infection in or about the affected hip joint or an infection distant from the affected hip joint that may spread to the affected joint hematogenously. 12) The patient has a known sensitivity or allergic reaction to any of the materials of the joint prosthesis including metal and ceramic. 13) The patient has an acute fracture in the affected femoral head that requires THA. 14) The patient has undergone THA, revision surgery or surface arthroplasty of the contralateral hip within the previous 6 months. 15) The patient has had previous girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated. 16) The patient has insufficient bone stock to fix the hip prostheses. 17) The patient has a local bone tumor or cyst in the affected hip joint. 18) The patient has a Body Mass Index (BMI) >35.
研究者
相似试验
已完成
2 期
Clinical evaluation effects of ZAX.1400.C01 in patients with coronavirusIncidence of inflammation due to the mechanism of COVID19.COVID-19U07.1IRCT20210218050404N2Fasa University of Medical Sciences60
尚未招募
1 期
BICICL: BTK and Immune Checkpoint Inhibitor in Central Nervous System (CNS) LymphomaCentral Nervous System LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12622000547741Monash University30
尚未招募
3 期
Evaluation of therapeutic effects of ZAX.1400.C05 on patients with coronavirusCOVID-19 viral disease.Coronavirus infection, unspecifiedB34.2IRCT20210218050404N4Fasa University of Medical Sciences300
尚未招募
2 期
Evaluation of clinical effectiveness of Zanthoxylum limonella Alston essential oil patch combined with Thai boxing exercise on parameter-related falls in elderly with risk of falling: a randomized placebo-controlled trialOlder adults with risk of fallingSeniorsfallingTCTR20211114002Thailand Science Research and Innovation (TSRI)74
已完成
2 期
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 DiabetesOverweight and ObesityType 2 Diabetes MellitusNCT03254368Zafgen, Inc.188